# US 2010/0168131 A1 · Novel compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168131 A1
- Document ID: US20100168131A1
- Status: Published application
- Kind: A1
- Application number: 12/627,283
- Filed: 2009-11-30
- Published: 2010-07-01
- Earliest claimed: 2008-12-02
- Assignees: Glaxo Group Limited
- Inventors: Giuseppe Alvaro; David Amantini; Emiliano Castiglioni; Romano Di Fabio; Francesca Pavone
- Web page: https://patentgrep.com/patent/US20100168131A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- C07D 401/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and their use as pharmaceuticals.

## Claims

### Claim 1

A compound of formula (I)
where:
Het is a heteroaryl group selected from the group consisting of pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl, said heteroaryl group being optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of: C1-4alkyl, halo, C1-4alkoxy, haloC1-4alkyl, haloC1-4alkoxy and cyano;
R1 is C1-4alkyl, halo, C1-4alkoxy, haloC1-4alkyl, haloC1-4alkoxy, cyano, C1-4alkylSO2, C3-8cycloalkylSO2, C3-8cycloalkylCH2SO2, phenyl or a 5 or 6 membered heterocyclyl group containing 1, 2 or 3 atoms selected from N, O or S, which phenyl or heterocyclyl group is optionally substituted with C1-4alkyl, halo, C1-4alkoxy, haloC1-4alkyl, haloC1-4alkoxy or cyano;
R2 is C1-4alkyl, halo, C1-4alkoxy, haloC1-4alkyl, haloC1-4alkoxy, cyano, phenyl or a 5 or 6 membered heterocyclyl group containing 1, 2 or 3 atoms selected from N, O or S, which phenyl or heterocyclyl group is optionally substituted with C1-4alkyl, halo, C1-4alkoxy, haloC1-4alkyl, haloC1-4alkoxy or cyano;
R3 is C1-4alkyl, halo, C1-4alkoxy, haloC1-4alkyl, haloC1-4alkoxy or cyano;
m is 0 or 1; and
n is 0 or 1;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound or salt according to claim 1, where Het is substituted with haloC1-4alkyl.

### Claim 3 (depends on 2)

The compound or salt according to claim 2, where Het is substituted with trifluoromethyl.

### Claim 4 (depends on 1)

The compound or salt according to claim 1, where Het is pyridinyl.

### Claim 5 (depends on 1)

The compound or salt according to claim 1, where Het is pyrimidinyl.

### Claim 6 (depends on 4)

The compound or salt according to claim 4, where Het is pyridinyl substituted with trifluoromethyl or cyano.

### Claim 7 (depends on 1)

The compound or salt according to claim 1, where m is 0 and n is 0.

### Claim 8 (depends on 1)

The compound or salt according to claim 1, where m is 1 and n is 0.

### Claim 9 (depends on 1)

The compound or salt according to claim 1, where R1 is CH3.

### Claim 10 (depends on 1)

The compound or salt according to claim 1, where R2 is methoxy, ethoxy, propoxy, phenyl, pyrimidinyl, oxadiazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, imidazolyl, pyrazolinyl, pyridazinyl, pyrazinyl or pyridinyl.

### Claim 11 (depends on 10)

The compound or salt according to claim 10, where R2 is pyrimidinyl.

### Claim 12 (depends on 1)

The compound or salt according to claim 1, where Het is pyridinyl substituted with trifluoromethyl, m is 1, n is 0, R1 is CH3 and R2 is pyrimidinyl.

### Claim 13 (depends on 1)

The compound or salt according to claim 1, where Het is pyrazinyl substituted with trifluoromethyl, m is 1, n is 0, R1 is CH3 and R2 is pyrimidinyl.

### Claim 14

A compound selected from the group consisting of:
N-[((1S,4S,6S)-3-{[6-methyl-3-(propyloxy)-2-pyridinyl]carbonyl}-3-azabicyclo [4.1.0]hept-4-yl)methyl]-5-(trifluoromethyl)-2-pyridinamine;
N-[((1S,4S,6S)-3-{[3-(ethyloxy)-6-methyl-2-pyridinyl]carbonyl}-3-azabicyclo[4.1.0]hept-4-yl)methyl]-5-(trifluoromethyl)-2-pyridinamine;
N-[((1S,4S,6S)-3-{[6-methyl-3-(2-pyrimidinyl)-2-pyridinyl]carbonyl}-3-azabicyclo [4.1.0]hept-4-yl)methyl]-5-(trifluoromethyl)-2-pyridinamine;
N-[((1S,4S,6S)-3-{[6-methyl-3-(2-pyrimidinyl)-2-pyridinyl]carbonyl}-3-azabicyclo [4.1.0]hept-4-yl)methyl]-5-(trifluoromethyl)-2-pyrazinamine;
N-[((1S,4S,6S)-3-{[6-methyl-3-(1H-pyrazol-1-yl)-2-pyridinyl]carbonyl}-3-azabicyclo[4.1.0]hept-4-yl)methyl]-5-(trifluoromethyl)-2-pyrazinamine; and
N-[((1S,4S,6S)-3-{[6-methyl-3-(2H-1,2,3-triazol-2-yl)-2-pyridinyl]carbonyl}-3-azabicyclo[4.1.0]hept-4-yl)methyl]-5-(trifluoromethyl)-2-pyrazinamine;
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

A method for the treatment of a disease or disorder where an antagonist of a human orexin receptor is required, in a subject in need thereof, comprising administering to said subject an effective amount of the compound or salt according to claim 1, where the disease or disorder is a sleep disorder, a depression or mood disorder, an anxiety disorder, a substance-related disorder or a feeding disorder.

### Claim 16 (depends on 15)

The method according to claim 15, where the disease or disorder is a sleep disorder.

### Claim 17 (depends on 15)

The method according to claim 15, where the sleep disorder is insomnia.

### Claim 18 (depends on 15)

The method according to claim 15, where the sleep disorder is selected from the group consisting of Primary Insomnia; Breathing-Related Sleep Disorders; Circadian Rhythm Sleep Disorder; Dyssomnia Not Otherwise Specified; Nightmare Disorder; Sleep Tenor Disorder; Sleepwalking Disorder; Parasomnia Not Otherwise Specified; Insomnia Related to Another Mental Disorder; insomnia associated with a disease selected from a neurological disorder, neuropathic pain, restless leg syndrome, heart disease and lung disease; Insomnia Type Substance-Induced Sleep Disorder; Parasomnia Type Substance-Induced Sleep Disorder; Mixed Type Substance-Induced Sleep Disorder; Sleep Apnea; and Jet-Lag Syndrome.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising the compound or salt according to claim 1 and one or more pharmaceutically acceptable carriers.

### Claim 20 (depends on 14)

A pharmaceutical composition comprising the compound or salt according to claim 14 and one or more pharmaceutically acceptable carriers.
